REGISTER
Prof. Tyler F. Stewart on How KEYNOTE-B15 May Transform MIBC Treatment
Prof. Stewart provides an in-depth interpretation of the phase III KEYNOTE-B15 trial and its potential to reshape the treatment landscape for muscle-invasive bladder cancer (MIBC).

Prof. Tyler F. Stewart, UC San Diego Health, United States

Prof. Stewart provides an in-depth interpretation of the phase III KEYNOTE-B15 trial and its potential to reshape the treatment landscape for muscle-invasive bladder cancer (MIBC). He also looks ahead to the evolving therapeutic paradigm, discussing how the combination of enfortumab vedotin (EV) and pembrolizumab may drive a new era of treatment strategies in bladder cancer.

Watch the full interview for comprehensive expert insights.

0
0
Loading